ORION: A Phase 2, randomized, multicenter, double-blind study to assess efficacy and safety of durvalumab+olaparib vs durvalumab alone as maintenance therapy in Stage IV non-small cell lung cancer (NSCLC).

Myung-Ju Ahn,Yufan Liu,Teresa Improta,Michelle Marcovitz,Kate DiPiazza,M Lanasa

ORION: A Phase 2, randomized, multicenter, double-blind study to assess efficacy and safety of durvalumab+olaparib vs durvalumab alone as maintenance therapy in Stage IV non-small cell lung cancer (NSCLC).

2019

Myung-Ju Ahn
Yufan Liu
Teresa Improta
Michelle Marcovitz
Kate DiPiazza
M Lanasa

TPS9126Background: Systemic chemotherapy for first-line (1L) metastatic NSCLC shows mixed outcomes. Results from studies using immunotherapy alone or combined with chemotherapy as 1L treatment in p...

Keywords:

Immunotherapy
Olaparib
Durvalumab
Oncology
Stage IV non-small cell lung cancer
Internal medicine
Maintenance therapy
Pathology
Chemotherapy
Medicine
double blind study
systemic chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations